17ß-hydroxysteroid dehydrogenase type 13 (HSD17B13) iRNA compositions and methods of use thereof
Gregory Hinkle, Plymouth, MA (US); Frederic Tremblay, Boston, MA (US); Noura S. Abul-Husn, New York, NY (US); Omri Gottesman, Rancho Santa Fe, CA (US); Alexander Li, White Plains, NY (US); Xiping Cheng, Northvale, NJ (US); Yurong Xin, Ashland, MA (US); Jesper Gromada, Concord, MA (US); Frederick E. Dewey, Winchester, MA (US); Aris Baras, Bedford Corners, NY (US); Alan Shuldiner, Baltimore, MD (US); and Stuart Milstein, Arlington, MA (US)
Assigned to Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Appl. No. 16/978,947
Filed by Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
PCT Filed Mar. 20, 2019, PCT No. PCT/US2019/023079 § 371(c)(1), (2) Date Sep. 8, 2020, PCT Pub. No. WO2019/183164, PCT Pub. Date Sep. 26, 2019.
Claims priority of provisional application 62/775,590, filed on Dec. 5, 2018.
Claims priority of provisional application 62/770,298, filed on Nov. 21, 2018.
Claims priority of provisional application 62/645,941, filed on Mar. 21, 2018.
Prior Publication US 2021/0380985 A1, Dec. 9, 2021
1. A method of inhibiting 17β-hydroxysteroid dehydrogenase type 13 (HSD17B13) expression in a cell, comprising contacting the cell with a double stranded ribonucleic acid (dsRNA) agent, wherein the dsRNA agent comprises a sense strand and an antisense strand, wherein the nucleotide sequence of the sense strand comprises the nucleotide sequence of SEQ ID NO: 4498 and the nucleotide sequence of the antisense strand comprises the nucleotide sequence of SEQ ID NO: 4499, thereby inhibiting expression of HSD17B13 in the cell.